Two biotechs sign reverse mergers to advance I&I drug, BTK inhibitor
A biotech with a bispecific antibody from China and a little-known San Diego startup with a BTK inhibitor from Gossamer Bio have each signed reverse mergers to take their experimental medicines onto the Nasdaq. Caldera ...
July 29, 2026 10:46 AM EDT Deals Two biotechs sign reverse mergers to advance I&I drug, BTK inhibitor Kyle LaHucik Biotech Correspondent A biotech with a bispecific antibody from China and a little-known San Diego startup with a BTK inhibitor from Gossamer Bio have each signed reverse … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that